A topical gel nanoformulation of amphotericin B (AmB) for the treatment of cutaneous leishmaniasis (CL)
Source abstract
Abstract
This study aimed to improve the water solubility and cutaneous permeability of Amphotericin B (AmB) for the topical treatment of Leishmania major-induced cutaneous leishmaniasis (CL) using two topical liposome-and polyethylene glycol (PEG)ylated liposome-gel formulations. The topical gel formulations of AmB were developed by its encapsulation into liposome (Lip-AmB) and (PEG)ylated liposome (PEG-Lip-AmB) using the reverse-phase evaporation method. The nanoformulations were characterized using dynamic light scattering and spectrophotometry. Their biological effects were evaluated in vitro and in vivo using Wright-Giemsa staining, limiting dilution assay, and pathological studies. Lip-AmB and PEG-Lip-AmB with the size of 257 +/- 12.5 nm and 237 +/- 12 nm, respectively, were synthesized. PEG-Lip-AmB compared to Lip-AmB, was more potent to decrease the drug toxicity and increase the drug's therapeutic effects. The results of in vivo studies were in agreement with the results of in vitro studies, in which PEG-Lip-AmB-loaded gel (PEG-Lip-AmB-Gel), compared to Lip-AmB-loaded gel, could decrease the lesion size and parasite burden by 1.7-and 1.6-fold, respectively. These results suggest PEG-Lip-AmB-Gel can be used as a promising carrier to improve the properties of AmB for topical application against CL.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Research on Leishmaniasis Studies · Toxin Mechanisms and Immunotoxins · Urticaria and Related Conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Lanza JS, Pomel S, Loiseau PM, Frézard F (2019) Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opin drug Deliv 16(10):1063–107910.1080/17425247.2019.1659243 ↗
2. Majumder S, Das N, Pandey N, Srivastava T, Ghosha D (2018) Synthesis, characterization of novel PLGA encapsulated indole nanoparticles and study of its cytotoxic potential against A549 lung cancer cell line. J Appl Pharm Sci 8(08):144–150
3. Mostafavi M, Sharifi I, Farajzadeh S, Khazaeli P, Sharifi H, Pourseyedi E, Kakooei S, Bamorovat M, Keyhani A, Parizi MH (2019) Niosomal formulation of amphotericin B alone and in combination with glucantime: in vitro and in vivo leishmanicidal effects. Biomedicine Pharmacother 116:10894210.1016/j.biopha.2019.108942 ↗
4. Lalatsa A, Statts L, de Jesus JA, Adewusi O, Dea-Ayuela MA, Bolas-Fernandez F, Laurenti MD, Passero LFD, Serrano DR (2020) Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis. Int J Pharmaceutics 588:11973410.1016/j.ijpharm.2020.119734 ↗
5. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, Team WLC (2012) Leishmaniasis worldwide and global estimates of its incidence. PloS one 7(5):e3567110.1371/journal.pone.0035671 ↗
6. Wijnant G-J, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL (2017) AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy. Antimicrob Agents Chemother
7. Fernández-García R, Statts L, de Jesus JA, Dea-Ayuela MA, Bautista L, Simao R, Bolas-Fernandez F, Ballesteros MP, Laurenti MD, Passero LF (2020) Ultradeformable lipid vesicles localize amphotericin B in the dermis for the treatment of infectious skin diseases. ACS Infect Dis 6(10):2647–266010.1021/acsinfecdis.0c00293 ↗
8. Ammar AA, Nasereddin A, Ereqat S, Dan-Goor M, Jaffe CL, Zussman E, Abdeen Z (2019) Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis. Drug Deliv Transl Res 9(1):76–8410.1007/s13346-018-00603-0 ↗
9. Zahin N, Anwar R, Tewari D, Kabir M, Sajid A, Mathew B, Uddin M, Aleya L, Abdel-Daim MM (2020) Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery. Environ Sci Pollut Res 27(16):19151–1916810.1007/s11356-019-05211-0 ↗
10. Alavi SE, Ebrahimi Shahmabadi H (2021) Anthelmintics for drug repurposing: opportunities and challenges. Saudi. Pharm J: SPJ 29(5):434
11. Alavi SE, Raza A, Koohi Moftakhari Esfahani M, Akbarzadeh A, Abdollahi SH, Ebrahimi Shahmabadi H (2022) Carboplatin niosomal nanoplatform for potentiated chemotherapy. J Pharm Sci10.1016/j.xphs.2022.06.002 ↗
12. Koohi Moftakhari Esfahani M, Alavi SE, Cabot PJ, Islam N, Izake EL (2022) β-Lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cells. Pharmaceutics 14(4):88410.3390/pharmaceutics14040884 ↗
13. Ghaferi M, Koohi Moftakhari Esfahani M, Raza A, Al Harthi S, Ebrahimi Shahmabadi H, Alavi SE (2021) Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances. J Drug Target 29(2):131–15410.1080/1061186X.2020.1812614 ↗
14. Ghaferi M, Amari S, Vivek Mohrir B, Raza A, Ebrahimi Shahmabadi H, Alavi SE (2020) Preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities. Pharmaceuticals 13(3):4410.3390/ph13030044 ↗
15. Koohi Moftakhari Esfahani M, Alavi SE, Shahbazian S, Ebrahimi Shahmabadi H (2018) Drug delivery of cisplatin to breast cancer by polybutylcyanoacrylate nanoparticles. Adv Polym Technol 37(3):674–67810.1002/adv.21709 ↗
16. Ghaferi M, Zahra W, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE (2022) Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: an in vitro study. EXCLI J 21:236–249
17. Alavi SE, Raza A, Gholami M, Giles M, Al-Sammak R, Ibrahim A, Ebrahimi Shahmabadi H, Sharma LA(2022) Advanced drug delivery platforms for the treatment of oral pathogen. Pharmaceutics 14(11):229310.3390/pharmaceutics14112293 ↗
18. Koohi Moftakhari Esfahani M, Alavi SE, Cabot PJ, Islam N, Izake EL (2021) PEGylated mesoporous silica nanoparticles (mcm-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells. Pharmaceutics 13(10):160510.3390/pharmaceutics13101605 ↗
19. Hatamihanza H, Alavi SE, Ebrahimi Shahmabadi H, Akbarzadeh A (2020) Preparation, characterization and immunostimulatory effects of CRD2 and CRD3 from TNF Receptor-1 encapsulated into pegylated liposomal nanoparticles. Int J Pept Res Ther 26(2):745–75310.1007/s10989-019-09882-8 ↗
20. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101–12410.1038/s41573-020-0090-8 ↗
21. Alavi SE, Koohi Moftakhari Esfahani M, Ghassemi S, Akbarzadeh A, Hassanshahi G (2014) In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea. Indian J Clin Biochem 29(1):84–8810.1007/s12291-013-0315-2 ↗
22. Alavi SE, Koohi Moftakhari Esfahani M, Raza A, Adelnia H, Ebrahimi Shahmabadi H (2022) PEG-grafted liposomes for enhanced antibacterial and antibiotic activities: an in vivo study. NanoImpact:10038410.1016/j.impact.2022.100384 ↗
23. Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J pharm biopharm 93:52–7910.1016/j.ejpb.2015.03.018 ↗
24. Mishra GP, Bagui M, Tamboli V, Mitra AK (2011) Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 201110.1155/2011/863734 ↗
25. Lamichhane N, Udayakumar TS, D’Souza WD, Simone II CB, Raghavan SR, Polf J, Mahmood J (2018) Liposomes: clinical applications and potential for image-guided drug delivery. Molecules 23(2):28810.3390/molecules23020288 ↗
26. Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE (2020) Enhanced efficacy of PEGylated liposomal cisplatin: In vitro and in vivo evaluation. Int J Mol Sci 21(2):55910.3390/ijms21020559 ↗
27. Movahedi F, Ebrahimi Shahmabadi H, Alavi SE, Koohi Moftakhari Esfahani M (2014) Release modeling and comparison of nanoarchaeosomal, nanoliposomal and pegylated nanoliposomal carriers for paclitaxel. Tumor Biol 35(9):8665–867210.1007/s13277-014-2125-4 ↗
28. Ghaferi M, Raza A, Koohi M, Zahra W, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE (2022) Impact of PEGylated liposomal doxorubicin and carboplatin combination on glioblastoma. Pharmaceutics 14(10):218310.3390/pharmaceutics14102183 ↗
29. Alavi SE, Cabot PJ, Raza A, Moyle PM (2021) Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity. Bioconjugate Chem 32(4):810–82010.1021/acs.bioconjchem.1c00091 ↗
30. Alavi SE, Cabot PJ, Yap GY, Moyle PM (2020) Optimized methods for the production and bioconjugation of site-specific, alkyne-modified glucagon-like peptide-1 (GLP-1) analogs to azide-modified delivery platforms using copper-catalyzed alkyne–azide cycloaddition. Bioconjugate Chem 31(7):1820–183410.1021/acs.bioconjchem.0c00291 ↗
31. Alavi SE, Panah N, Page F, Gholami M, Dastfal A, Sharma LA, Shahmabadi HE (2022) Hydrogel-based therapeutic coatings for dental implants. Eur Polym J 181:11165210.1016/j.eurpolymj.2022.111652 ↗
32. Jain S, Kumar D, Swarnakar NK, Thanki K (2012) Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33(28):6758–6768. https://doi.org/10.1016/j.biomaterials.2012.05.02610.1016/j.biomaterials.2012.05.026 ↗
33. Shaikh MS, Kale MA (2020) Formulation and molecular docking simulation study of luliconazole nanosuspension–based nanogel for transdermal drug delivery using modified polymer. Materials Today. Chemistry 18:100364
34. Panonnummal R, Jayakumar R, Sabitha M (2017) Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream. Eur J Pharm Sci 96:193–20610.1016/j.ejps.2016.09.007 ↗
35. Kavian Z, Alavizadeh SH, Golmohamadzadeh S, Badiee A, Khamesipour A, Jaafari MR (2019) Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. Acta tropica 196:142–14910.1016/j.actatropica.2019.05.018 ↗
36. Tavares GS, Mendonça DV, Miyazaki CK, Lage DP, Soyer TG, Carvalho LM, Ottoni FM, Dias DS, Ribeiro PA, Antinarelli LM (2019) A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. Parasitol Int 68(1):63–7210.1016/j.parint.2018.10.005 ↗
37. Bhagat V, Pandit RA, Ambapurkar S, Sengar M, Kulkarni AP (2021) Drug interactions between antimicrobial and immunosuppressive agents in solid organ transplant recipients. Indian J Crit Care Med: Peer-reviewed, Off Publ Indian Soc Crit Care Med 25(1):6710.5005/jp-journals-10071-23439 ↗
38. Budai L, Kaszás N, Gróf P, Lenti K, Maghami K, Antal I, Klebovich I, Petrikovics I, Budai M (2013) Liposomes for topical use: a physico-chemical comparison of vesicles prepared from egg or soy lecithin. Sci pharmaceutica 81(4):1151–116610.3797/scipharm.1305-11 ↗
39. Zhong J, Huang H-L, Li J, Qian F-C, Li L-Q, Niu P-P, Dai L-C (2015) Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 14(1):82–8910.1016/S1499-3872(15)60336-8 ↗
40. Liu M, Zhang X, Yang B, Deng F, Ji J, Yang Y, Huang Z, Zhang X, Wei Y (2014) Luminescence tunable fluorescent organic nanoparticles from polyethyleneimine and maltose: facile preparation and bioimaging applications. RSC Adv 4(43):22294–2229810.1039/c4ra03103b ↗
41. Najlah M, Said Suliman A, Tolaymat I, Kurusamy S, Kannappan V, Elhissi A, Wang W (2019) Development of injectable PEGylated liposome encapsulating disulfiram for colorectal cancer treatment. Pharmaceutics 11(11):61010.3390/pharmaceutics11110610 ↗
42. Abbina S, Parambath A (2018) PEGylation and its alternatives: a summary. Engineering of biomaterials for drug delivery systems. elsevier, pp 363–37610.1016/B978-0-08-101750-0.00014-3 ↗
43. Jiao Y, Li D, Liu C, Chang Y, Song J, Xiao Y (2018) Polypeptide–decorated nanoliposomes as novel delivery systems for lutein. RSC Adv 8(55):31372–3138110.1039/C8RA05838E ↗
44. Worldwide MI (2011) Dynamic light scattering, common terms defined. Inform white paper malvern, UK: malvern Instruments Limited:1–6
45. Gnoatto JA, Morás AM, de Oliveira JV, Arndt E, Dallegrave A, da Cunha ACB, Moura DJ, dos Santos JHZ (2022) PEGylated and zwitterated silica nanoparticles as doxorubicin carriers applied in a breast cancer cell line: effects on protein corona formation. J Drug Deliv Sci Technol 71:10332510.1016/j.jddst.2022.103325 ↗
46. Musumeci T, Bonaccorso A, Carbone C, Russo G, Pappalardo F, Puglisi G (2019) Design and optimization of PEGylated nanoparticles intended for Berberine Chloride delivery. J Drug Deliv Sci Technol 52:521–530. https://doi.org/10.1016/j.jddst.2019.05.01210.1016/j.jddst.2019.05.012 ↗
47. Kang B-S, Choi J-S, Lee S-E, Lee J-K, Kim T-H, Jang WS, Tunsirikongkon A, Kim J-K, Park J-S (2017) Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. Carbohydr Polym 159:39–4710.1016/j.carbpol.2016.12.009 ↗
48. Tyrrell ZL, Shen Y, Radosz M (2010) Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog Polym Sci 35(9):1128–114310.1016/j.progpolymsci.2010.06.003 ↗
49. Cai D, Gao W, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q (2014) Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials 35(7):2283–229410.1016/j.biomaterials.2013.11.088 ↗
50. Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H (2014) Safety of nanoparticles in medicine. Curr Drug Targets 15:1–310.2174/138945011501140115104533 ↗
51. Alavi SE, Muflih Al Harthi S, Ebrahimi Shahmabadi H, Akbarzadeh A (2019) Cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved properties as an anticancer agent. Int J Mol Sci 20(7):153110.3390/ijms20071531 ↗
52. Yu L, Dong A, Guo R, Yang M, Deng L, Zhang J (2018) DOX/ICG coencapsulated liposome-coated thermosensitive nanogels for NIR-triggered simultaneous drug release and photothermal effect. ACS Biomater Sci Eng 4(7):2424–243410.1021/acsbiomaterials.8b00379 ↗
53. Jaafari MR, Hatamipour M, Alavizadeh SH, Abbasi A, Saberi Z, Rafati S, Taslimi Y, Mohammadi AM, Khamesipour A (2019) Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. Int J parasitology: drugs drug resistance 11:156–165
54. Alavi SE, Ebrahimi Shahmabadi H (2021) GLP-1 peptide analogs for targeting pancreatic beta cells. Drug Discov Today10.1016/j.drudis.2021.03.032 ↗
55. Rangsimawong W, Opanasopit P, Rojanarata T, Duangjit S, Ngawhirunpat T (2016) Skin transport of hydrophilic compound-loaded PEGylated lipid nanocarriers: comparative study of liposomes, niosomes, and solid lipid nanoparticles. Biol Pharm Bull 39(8):1254–126210.1248/bpb.b15-00981 ↗
56. El Maghraby GM, Williams AC (2009) Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv 6(2):149–16310.1517/17425240802691059 ↗
57. Knudsen NØ, Rønholt S, Salte RD, Jorgensen L, Thormann T, Basse LH, Hansen J, Frokjaer S, Foged C (2012) Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharmaceutics Biopharmaceutics 81(3):532–53910.1016/j.ejpb.2012.04.005 ↗
58. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1(3):29710.2217/17435889.1.3.297 ↗
59. Moribe K, Shibata M, Furuishi T, Higashi K, Tomono K, Yamamoto K (2010) Effect of particle size on skin permeation and retention of piroxicam in aqueous suspension. Chem Pharm Bull 58(8):1096–109910.1248/cpb.58.1096 ↗
60. Gonzalez LE, Boylan PM (2021) Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review. Ann Pharmacother 55(8):1025–103610.1177/1060028020971215 ↗